147 related articles for article (PubMed ID: 30581091)
1. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
Ren H; Hou X; Eiken PW; Zhang J; Pierson KE; Nair AA; Davila JI; Kovarikova H; Jang JS; Johnson SH; Molina JR; Marks RS; Yang P; Yi JE; Mansfield AS; Jen J
Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
[No Abstract] [Full Text] [Related]
2. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
3. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
Yang L; Zhao W; Zhu H; Li X; Zhao G
Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
[No Abstract] [Full Text] [Related]
4. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
5. Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.
Nikitski AV; Rominski SL; Wankhede M; Kelly LM; Panebianco F; Barila G; Altschuler DL; Nikiforov YE
Am J Pathol; 2018 Nov; 188(11):2653-2661. PubMed ID: 30125543
[TBL] [Abstract][Full Text] [Related]
6. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.
Zhang L; Xiao P; Meng F; Zhong D
Curr Oncol; 2022 Sep; 29(10):6749-6753. PubMed ID: 36290807
[TBL] [Abstract][Full Text] [Related]
7. PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
Wang B; Chen R; Wang C; Chen H; Zhong D
Lung Cancer; 2021 Mar; 153():176-178. PubMed ID: 33483162
[No Abstract] [Full Text] [Related]
8. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.
Hou X; Xu H; Chen L
J Thorac Oncol; 2019 Apr; 14(4):e72-e73. PubMed ID: 30922581
[No Abstract] [Full Text] [Related]
9. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
Luo J; Gu D; Lu H; Liu S; Kong J
J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
[No Abstract] [Full Text] [Related]
11. A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
He Z; Zhu X; Zeng Q; Yu Z
Lung Cancer; 2021 Aug; 158():164-165. PubMed ID: 34120772
[No Abstract] [Full Text] [Related]
12. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
Liang Y; Wang Y; Wang W; Zhao J; Xu M; Zheng M
Clin Genet; 2021 Mar; 99(3):488-489. PubMed ID: 33556194
[TBL] [Abstract][Full Text] [Related]
13. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ; Mittempergher L; Davidson NM; Bosma A; Willems SM; Horlings HM; de Rink I; Greger L; Hooijer GK; Peters D; Nederlof PM; Hofland I; de Jong J; Wesseling J; Kluin RJ; Brugman W; Kerkhoven R; Nieboer F; Roepman P; Broeks A; Muley TR; Jassem J; Niklinski J; van Zandwijk N; Brazma A; Oshlack A; van den Heuvel M; Bernards R
J Pathol; 2013 Jul; 230(3):270-6. PubMed ID: 23661334
[TBL] [Abstract][Full Text] [Related]
14. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
Zhang J; Huang J; Li Q; Lin H; Luo Z; Chen R
Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
[No Abstract] [Full Text] [Related]
15. TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
Mao W; Chen R; Zhang J; Zheng M
J Thorac Oncol; 2020 Mar; 15(3):e37-e39. PubMed ID: 32093858
[No Abstract] [Full Text] [Related]
16. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Dou Y; Duan Q; Qi C; Hou L; Wang H
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1865-1867. PubMed ID: 33544200
[TBL] [Abstract][Full Text] [Related]
17. Detection of STRN-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis.
Jurkiewicz M; Cimic A; Murty VV; Kuo JH; Hsiao S; Fazlollahi L; Fernandes H
Diagn Cytopathol; 2021 Apr; 49(4):E146-E151. PubMed ID: 33085842
[TBL] [Abstract][Full Text] [Related]
18. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
19. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
Fang W; Gan J; Hong S; Lu F; Zhang L
J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
[No Abstract] [Full Text] [Related]
20. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
